Download Sample
Add to CartGlobal Psoriasis Treatment Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Drug Class;
TNF Inhibitors, Interleukins Inhibitors, and Others.By Type;
Plaque Psoriasis, Psoriatic Arthritis, and Others.By Product;
Tumor Necrosis Factor Inhibitors - [Adalimumab, Infliximab, and Etanercept]By Distribution Channel;
Topicals - Over-The-Counter (OTC) Topicals, Topical Non-Steroids, and Topical Steroids.By Geography;
North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031).Psoriasis Treatment Market Overview
Psoriasis Treatment Market (USD Million)
Psoriasis Treatment Market was valued at USD 28,110.38 million in the year 2024. The size of this market is expected to increase to USD 49,535.08 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 8.4%.
Global Psoriasis Treatment Market Growth, Share, Size, Trends and Forecast
*Market size in USD million
CAGR 8.4 %
| Study Period | 2025 - 2031 |
|---|---|
| Base Year | 2024 |
| CAGR (%) | 8.4 % |
| Market Size (2024) | USD 28,110.38 Million |
| Market Size (2031) | USD 49,535.08 Million |
| Market Concentration | Medium |
| Report Pages | 387 |
Major Players
- Johnson & Johnson
- Novartis International AG
- Pfizer Inc.
- Eli Lilly and Company
- Amgen Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb
- Celgene Corporation
- UCB S.A.
Market Concentration
Consolidated - Market dominated by 1 - 5 major players
Global Psoriasis Treatment Market
Fragmented - Highly competitive market without dominant players
The psoriasis treatment market is expanding steadily, driven by the increasing incidence of chronic inflammatory skin conditions. Affecting nearly 2% to 3% of the global population, psoriasis demands consistent and long-term care. The persistent nature of this autoimmune disease underscores the need for effective therapeutic solutions, positioning the market for continuous growth.
Biologic Therapies Lead the Way in Innovation
Biologic treatments have become a cornerstone in managing moderate to severe psoriasis, contributing to more than 50% of the market’s total treatment value. These targeted therapies work by interfering with specific immune responses, providing better skin clearance and symptom relief. Their growing acceptance among healthcare providers reflects a shift toward personalized and high-efficacy treatment options.
Greater Awareness Enhances Early Treatment
Increased awareness campaigns and improved diagnostic methods are encouraging earlier detection and management of psoriasis. There has been a 35% rise in early diagnoses, enabling timely intervention and better treatment adherence. This trend supports market growth by emphasizing proactive care and sustained patient engagement.
Expanding Pipeline of Advanced Therapies
Research and development remain strong pillars of the market, with over 25% of ongoing trials focused on next-generation treatments such as new immunomodulators and improved topical agents. Innovation in formulation technologies is also aiming to reduce side effects and enhance patient experience, particularly for those with resistance to conventional therapies.
Supportive Regulations and Reimbursement Policies
Favorable healthcare regulations are playing a crucial role in market advancement. Currently, nearly 40% of healthcare programs include reimbursement provisions for biologic psoriasis treatments, making them more accessible. This policy support is increasing treatment affordability and fostering higher adoption rates across various patient populations.
Psoriasis Treatment Market Recent Developments
-
In 2023, biologics continued to dominate the psoriasis treatment market due to high efficacy in managing symptoms. New product launches by major players like AbbVie and Novartis expanded their influence, aiming to meet increased demand for advanced psoriasis therapies.
-
In 2022, the U.S. FDA granted fast-track designation to new oral treatments targeting severe plaque psoriasis, spurring further innovation and investment in next-generation therapies for chronic psoriasis management.
Psoriasis Treatment Market Segment Analysis
In this report, the Psoriasis Treatment Market has been segmented by Drug Class, Type, Product, Distrubution Channel and Geography.
Psoriasis Treatment Market, Segmentation by Drug Class
The Psoriasis Treatment Market has been segmented by Drug Class into TNF Inhibitors, Interleukins Inhibitors, and Others.
TNF Inhibitors
TNF inhibitors, including adalimumab, etanercept, and infliximab, play a key role in the treatment of moderate to severe psoriasis by targeting the tumor necrosis factor (TNF), a protein that drives inflammation. This drug class holds a significant share of approximately 45% in the global psoriasis treatment market, owing to its proven efficacy and widespread use in both dermatology and rheumatology settings.
Interleukins Inhibitors
Interleukin inhibitors, such as secukinumab and ixekizumab, work by targeting specific interleukins involved in the immune response, which is responsible for psoriasis inflammation. This class has gained increasing market share, accounting for about 35% of the global market. Interleukin inhibitors are particularly favored for their effectiveness in treating severe psoriasis cases that have not responded well to other therapies.
Others
The "Others" category includes various alternative treatments such as topical corticosteroids, methotrexate, and retinoids. These drugs account for approximately 20% of the market, offering less invasive options for managing mild to moderate psoriasis, or as adjuncts to biologic therapies.
Psoriasis Treatment Market, Segmentation by Type
The Psoriasis Treatment Market has been segmented by Type into Plaque Psoriasis, Psoriatic Arthritis, and Others.
Plaque Psoriasis
Plaque psoriasis is the most common type of psoriasis, characterized by raised, inflamed, red patches covered with silvery-white scales. This form of psoriasis holds the largest share of the market, approximately 70%. Treatment options include topical treatments like corticosteroids, biologics, and systemic therapies aimed at reducing inflammation and controlling flare-ups.
Psoriatic Arthritis
Psoriatic arthritis is a chronic autoimmune disease that affects both the skin and joints, leading to pain, swelling, and stiffness. This type of psoriasis treatment accounts for around 20% of the market. It is treated with disease-modifying antirheumatic drugs (DMARDs), biologics, and JAK inhibitors to reduce inflammation and prevent joint damage.
Others
The "Others" category includes rarer forms of psoriasis such as inverse psoriasis, guttate psoriasis, and erythrodermic psoriasis. This segment makes up about 10% of the market. Treatment for these forms varies, typically involving topical therapies, phototherapy, and systemic medications to control symptoms.
Psoriasis Treatment Market, Segmentation by Product
The Psoriasis Treatment Market has been segmented by Product into Tumour Necrosis Factor Inhibitors, Anticholinergics and Vitamin D Analogues.
Tumour Necrosis Factor Inhibitors
Tumour necrosis factor (TNF) inhibitors, such as adalimumab and etanercept, are widely used to treat moderate to severe psoriasis. These biologic drugs work by blocking TNF-alpha, a protein that causes inflammation. TNF inhibitors dominate the market, accounting for approximately 50% of the psoriasis treatment market due to their effectiveness in reducing flare-ups and improving the quality of life for patients.
Anticholinergics
Anticholinergic drugs, which help reduce the activity of acetylcholine, are occasionally used in psoriasis treatment to manage symptoms such as pruritus and inflammation. This product category holds a smaller share of the market, contributing around 15%. Anticholinergics are typically prescribed as adjuncts to other primary treatments, especially in cases of severe itching.
Vitamin D Analogues
Vitamin D analogues, such as calcipotriene and calcitriol, are commonly used for topical treatment of mild to moderate psoriasis. They work by regulating skin cell production and slowing down excessive skin growth. This product category contributes approximately 35% of the market, offering a preferred solution for many patients due to its non-systemic approach and minimal side effects.
Psoriasis Treatment Market, Segmentation by Distrubution Channel
The Psoriasis Treatment Market has been segmented by Distrubution Channel into Topicals - Over-The-Counter (OTC) Topicals, Topical Non-Steroids and Topical Steroids.
Topicals - Over-The-Counter (OTC) Topicals
Over-the-counter (OTC) topicals are widely used in the treatment of mild to moderate psoriasis. These include products such as coal tar, salicylic acid, and hydrocortisone creams. OTC topicals account for approximately 40% of the market, offering a cost-effective and accessible solution for patients seeking symptom relief without a prescription.
Topical Non-Steroids
Topical non-steroidal treatments, such as calcineurin inhibitors and Vitamin D analogs, are often used to manage psoriasis without the risk of steroid-related side effects. This category contributes around 35% of the market, providing an alternative to steroid-based treatments for patients with sensitive skin or those seeking long-term treatment options.
Topical Steroids
Topical steroids, including high-potency corticosteroids like clobetasol, are commonly prescribed to reduce inflammation and control flare-ups in moderate to severe psoriasis cases. This segment holds the largest market share, accounting for approximately 25% of the psoriasis treatment market, due to their proven effectiveness and fast-acting results.
Psoriasis Treatment Market, Segmentation by Geography
In this report, the Psoriasis Treatment Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Regions and Countries Analyzed in this Report
Psoriasis Treatment Market Share (%), by Geographical Region
North America
North America dominates the psoriasis treatment market, accounting for approximately 40% of the total market share. The U.S. leads the region, driven by advanced healthcare infrastructure, increased awareness of psoriasis, and the availability of innovative biologic treatments. The region's strong research and development investments further contribute to its market leadership.
Europe
Europe holds the second-largest share of the psoriasis treatment market, contributing around 30%. The market in Europe is driven by the increasing prevalence of psoriasis, along with the availability of advanced treatment options and a strong healthcare system. Key countries such as Germany, the UK, and France lead in adoption of biologics and systemic treatments.
Asia Pacific
The Asia Pacific region is witnessing rapid growth in the psoriasis treatment market, with a share of about 15%. Factors such as rising healthcare access, increased awareness of dermatological conditions, and a growing prevalence of psoriasis are contributing to market expansion. Countries like China, Japan, and India are seeing increased adoption of both topical and systemic treatments.
Middle East and Africa
The Middle East and Africa market holds a smaller share of approximately 10%, but it is growing steadily. The region's expanding healthcare infrastructure, along with increasing awareness of chronic skin conditions like psoriasis, is driving demand for treatment options. Countries like Saudi Arabia and South Africa are key contributors to market growth in this region.
Latin America
Latin America contributes around 5% to the psoriasis treatment market. The market is growing due to improvements in healthcare access, rising psoriasis awareness, and increasing adoption of modern treatment approaches, especially in countries like Brazil and Mexico.
Psoriasis Treatment Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Psoriasis Treatment Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Comprehensive Market Impact Matrix
This matrix outlines how core market forces—Drivers, Restraints, and Opportunities—affect key business dimensions including Growth, Competition, Customer Behavior, Regulation, and Innovation.
| Market Forces ↓ / Impact Areas → | Market Growth Rate | Competitive Landscape | Customer Behavior | Regulatory Influence | Innovation Potential |
|---|---|---|---|---|---|
| Drivers | High impact (e.g., tech adoption, rising demand) | Encourages new entrants and fosters expansion | Increases usage and enhances demand elasticity | Often aligns with progressive policy trends | Fuels R&D initiatives and product development |
| Restraints | Slows growth (e.g., high costs, supply chain issues) | Raises entry barriers and may drive market consolidation | Deters consumption due to friction or low awareness | Introduces compliance hurdles and regulatory risks | Limits innovation appetite and risk tolerance |
| Opportunities | Unlocks new segments or untapped geographies | Creates white space for innovation and M&A | Opens new use cases and shifts consumer preferences | Policy shifts may offer strategic advantages | Sparks disruptive innovation and strategic alliances |
Drivers, Restraints and Opportunity Analysis
Drivers
- Increasing Disease Prevalence
- Advancements in Therapeutic Options
-
Rising Awareness and Diagnosis - The psoriasis treatment market is expanding steadily, driven by growing awareness and improved diagnostic capabilities. Public health campaigns, educational outreach, and social media initiatives have played a major role in reshaping perceptions of psoriasis from being a simple skin issue to a chronic inflammatory condition with systemic implications. This has prompted more individuals to seek early medical intervention, increasing the number of diagnosed cases and fueling demand for effective treatment options.
Enhanced medical training and clinical awareness among healthcare providers are also contributing to this trend. With more widespread dissemination of diagnostic protocols and improved screening tools, clinicians are now identifying psoriasis at earlier stages and across its various subtypes. Timely diagnosis not only enables faster access to treatment but also helps prevent complications like psoriatic arthritis, boosting the uptake of both topical and systemic therapies.
Digital health innovations have further supported this market driver by making expert consultation more accessible. Teledermatology platforms, mobile health apps, and virtual diagnostic tools have enabled patients, particularly in rural or underserved areas, to obtain timely and accurate diagnoses. These technologies have opened up new patient segments to treatment options, increasing the volume of cases being actively managed and contributing to overall market growth.
As diagnosis becomes more frequent and awareness continues to grow, patients are increasingly proactive in managing their condition. This includes better adherence to prescribed therapies and greater interest in advanced biologics and personalized treatment regimens. Even individuals with mild to moderate symptoms are now more likely to pursue medical care, driving demand for a broader range of therapeutic solutions. These dynamics are positioning early diagnosis and patient awareness as key catalysts for long-term growth in the psoriasis treatment market.
Restraints
- High Cost of Biologic Therapies
- Side Effects Associated with Treatments
-
Stringent Regulatory Requirements - Continue to restrain the growth of the psoriasis treatment market. Developing and launching new therapies, particularly biologics and advanced topicals, demands compliance with highly detailed regulatory standards. Authorities such as the FDA and EMA require extensive clinical trial data to confirm the safety, efficacy, and long-term effects of each product. These rigorous requirements not only increase development costs but also delay the market entry of potentially life-changing treatments.
Pharmaceutical companies face numerous hurdles during the multi-phase approval process, including comprehensive safety assessments, immune response evaluations, and post-marketing surveillance. For psoriasis therapies that target the immune system, regulators demand detailed documentation on side effects and possible long-term complications. These burdensome protocols can discourage small and mid-sized companies from investing in innovation, especially when limited resources are available for extended clinical testing and regulatory submissions.
The dynamic nature of global regulatory landscapes adds another layer of difficulty. Frequent updates to clinical guidelines, increased scrutiny of biologic treatments, and changing approval benchmarks can interrupt ongoing research and extend timelines. Companies must invest in constant regulatory monitoring and adapt development strategies to stay aligned with new requirements. This ongoing adjustment contributes to rising operational costs and uncertainty during the product development lifecycle.
The lack of harmonization across international markets creates approval delays in regions with differing regulatory systems. Global product launches become fragmented, reducing access to innovative therapies and slowing commercial expansion. These persistent barriers hinder both the availability of advanced psoriasis treatments and the momentum of research and development. Unless regulatory processes are streamlined and unified, the market will continue to face challenges in delivering timely and effective solutions to patients worldwide.
Opportunities
- Development of Novel Therapies
- Growth of Biosimilars Market
-
Personalized Medicine Approaches - Unlocking new growth avenues in the psoriasis treatment market by enabling more tailored, patient-specific care. As scientific understanding of genetic predispositions, immune system behavior, and environmental triggers improves, healthcare providers are now able to customize therapies based on individual patient profiles. This approach improves treatment precision, reduces adverse reactions, and leads to better disease management, especially in cases where conventional treatments have failed.
The adoption of genetic and molecular diagnostics is playing a key role in identifying patient-specific biomarkers and immune pathways that drive psoriasis. These insights help determine the most appropriate biologic or systemic therapies, minimizing trial-and-error prescription practices. Personalized treatment not only enhances clinical effectiveness but also improves long-term patient engagement and therapy compliance, leading to faster symptom relief and greater quality of life.
Individualized care plans offer the advantage of real-time monitoring and adaptive treatment. By continuously assessing disease progression and therapeutic response, clinicians can fine-tune regimens to prevent flare-ups and avoid complications. This dynamic management style is particularly effective for patients with coexisting conditions such as psoriatic arthritis, metabolic disorders, or cardiovascular risks, ensuring their therapy is compatible with broader health goals.
The emergence of AI-powered tools and digital health technologies further strengthens the personalized medicine landscape. These platforms facilitate predictive analytics, treatment customization, and patient tracking, allowing for highly informed, data-driven decisions. As these innovations become more integrated into clinical workflows, personalized approaches are expected to become the standard of care in psoriasis treatment, significantly improving patient outcomes and propelling market growth.
Psoriasis Treatment Market Competitive Landscape Analysis
Key players in Psoriasis Treatment Market include:
- Johnson & Johnson
- Novartis International AG
- Pfizer Inc.
- Eli Lilly and Company
- Amgen Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb
- Celgene Corporation
- UCB S.A.
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Market Share Analysis
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Type
- Market Snapshot, By Product
- Market Snapshot, By Distrubution Channel
- Market Snapshot, By Region
- Psoriasis Treatment Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
- Increasing Disease Prevalence
- Advancements in Therapeutic Options
- Rising Awareness and Diagnosis
- Restraints
- High Cost of Biologic Therapies
- Side Effects Associated with Treatments
- Stringent Regulatory Requirements
- Opportunities
- Development of Novel Therapies
- Growth of Biosimilars Market
- Personalized Medicine Approaches
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Psoriasis Treatment Market, By Drug Class, By, 2021 - 2031 (USD Million)
- TNF Inhibitors
- Interleukins Inhibitors
- Others
- Psoriasis Treatment Market, By Type, 2021 - 2031 (USD Million)
- Plaque Psoriasis
- Psoriatic Arthritis
- Others
- Psoriasis Treatment Market, By Product, 2021 - 2031 (USD Million)
- Tumour Necrosis Factor Inhibitors
- Adalimumab
- Infliximab
- Etanercept
- Tumour Necrosis Factor Inhibitors
- Psoriasis Treatment Market, By Distrubution Channel, 2021 - 2031 (USD Million)
- Topicals
- Over-The-Counter (OTC) Topicals
- Topical Non-Steroids
- Topical Steroids
- Topicals
- Psoriasis Treatment Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Psoriasis Treatment Market, By Drug Class, By, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- Johnson & Johnson
- Novartis International AG
- Pfizer Inc.
- Eli Lilly and Company
- Amgen Inc.
- AbbVie Inc.
- Merck & Co., Inc.
- Bristol-Myers Squibb
- Celgene Corporation
- UCB S.A.
- Company Profiles
- Analyst Views
- Future Outlook of the Market